Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GBT TSE:TRZ CVE:ZMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsTRZTransat A.T.C$2.78+1.1%C$2.72C$1.41▼C$3.25C$111.56M1.22155578,733 shs65,968 shsZMAZoomAway TechnologiesC$0.07+27.3%C$0.07C$0.03▼C$0.09C$1.35M0.84508119,408 shs8,871 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%TRZTransat A.T.0.00%-4.51%-3.17%+6.18%+51.10%ZMAZoomAway Technologies0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsTRZTransat A.T.C$2.78+1.1%C$2.72C$1.41▼C$3.25C$111.56M1.22155578,733 shs65,968 shsZMAZoomAway TechnologiesC$0.07+27.3%C$0.07C$0.03▼C$0.09C$1.35M0.84508119,408 shs8,871 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%TRZTransat A.T.0.00%-4.51%-3.17%+6.18%+51.10%ZMAZoomAway Technologies0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGBTGlobal Blood Therapeutics 0.00N/AN/AN/ATRZTransat A.T. 1.83ReduceC$3.2715.96% UpsideZMAZoomAway Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRZ, ZMA, and GBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025TRZTransat A.T.ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperformC$2.00 ➝ C$2.259/12/2025TRZTransat A.T.DesjardinsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHoldC$3.25 ➝ C$3.009/4/2025TRZTransat A.T.CIBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperformC$2.25 ➝ C$2.609/3/2025TRZTransat A.T.National BanksharesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Sector PerformC$2.25 ➝ C$3.009/2/2025TRZTransat A.T.National Bank FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/16/2025TRZTransat A.T.TD SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuyC$4.75 ➝ C$5.50(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGBTGlobal Blood Therapeutics$194.75M23.73N/AN/A$3.05 per share22.46TRZTransat A.T.C$3.39B0.03C$9.41 per share0.30C($22.89) per share-0.12ZMAZoomAway TechnologiesC$319.70K4.23C$0.00 per share17.73C($0.34) per share-0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGBTGlobal Blood Therapeutics-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/ATRZTransat A.T.-C$116.59M-C$3.62N/A∞N/A-3.47%12.83%-1.38%N/AZMAZoomAway Technologies-C$1.22M-C$0.07N/A∞N/A-298.84%N/A-352.79%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGBTGlobal Blood TherapeuticsN/AN/AN/AN/AN/ATRZTransat A.T.N/A4.81%N/AN/AN/AZMAZoomAway TechnologiesN/A6.65%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGBTGlobal Blood Therapeutics4.926.886.17TRZTransat A.T.-241.600.810.76ZMAZoomAway TechnologiesN/A0.010.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGBTGlobal Blood TherapeuticsN/ATRZTransat A.T.0.10%ZMAZoomAway Technologies0.09%Insider OwnershipCompanyInsider OwnershipGBTGlobal Blood Therapeutics4.90%TRZTransat A.T.0.04%ZMAZoomAway Technologies6.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGBTGlobal Blood Therapeutics45767.48 million64.17 millionOptionableTRZTransat A.T.5,00040.13 millionN/ANot OptionableZMAZoomAway TechnologiesN/A19.33 millionN/ANot OptionableTRZ, ZMA, and GBT HeadlinesRecent News About These CompaniesZoomAway Technologies Inc.: Zoomaway Announces Two Changes to Board of DirectorsJanuary 24, 2025 | finanznachrichten.deYahoo Tech | Technology News, Updates, Reviews & StoriesOctober 31, 2024 | yahoo.comThe Power of ZMA: Unlocking Better Sleep and Recovery for AthletesOctober 17, 2024 | healthtechzone.comHTurkey unveils ZMA-X: Revolutionizing robotic warfareOctober 3, 2024 | msn.comTurkish innovation: ZMA-X combat robot unveiled at teknofestOctober 3, 2024 | msn.comZoomAway Technologies: Top 10 Undervalued Travel & Leisure Industry Stocks (ZMA)May 7, 2024 | theglobeandmail.comZoomAway Technologies Inc.: ZoomAway Announces Proposed Change of Business to Investment IssuerMay 6, 2024 | finanznachrichten.deCanadian Investment Regulatory Organization Trading Halt - ZMAMay 6, 2024 | ca.finance.yahoo.comZoomAway Technologies Full Year 2023 Earnings: US$0.039 loss per share (vs US$0.11 loss in FY 2022)May 2, 2024 | finance.yahoo.comPool Safe: Top 10 Undervalued Consumer Cyclical Sector Stocks on TSX-V (POOL)February 20, 2024 | theglobeandmail.comZoomAway Technologies Inc. (ZMA.V)November 27, 2023 | ca.finance.yahoo.comZoomAway Closes Private PlacementNovember 21, 2023 | finance.yahoo.comZoomAway Technologies Inc.: ZoomAway Closes Private PlacementNovember 20, 2023 | finanznachrichten.deZoomAway Technologies Inc.: ZoomAway Announces Proposed Private PlacementNovember 6, 2023 | finanznachrichten.deZoomAway Announces Proposed Private PlacementNovember 6, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - ZMAOctober 25, 2023 | finance.yahoo.comZoomAway Provides Corporate Update And Announces Resumption Of TradingOctober 24, 2023 | finance.yahoo.comZMA.V - ZoomAway Technologies Inc.June 24, 2023 | ca.finance.yahoo.comZoomAway Technologies Stock (OTC:ZMWYF), Analyst Ratings, Price Targets, PredictionsOctober 29, 2022 | benzinga.comZoomAway Technologies Inc.: ZoomAway has Entered into Binding Letter of Intent to Acquire Large Ontario-Based Retailer and will Spin Out Travel AssetsApril 12, 2022 | finanznachrichten.deMedia Sentiment Over TimeTRZ, ZMA, and GBT Company DescriptionsGlobal Blood Therapeutics NASDAQ:GBTGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Transat A.T. TSE:TRZC$2.78 +0.03 (+1.09%) As of 02:41 PM EasternTransat A.T. Inc is a Canadian company that specializes in the organization, marketing, and distribution of holiday travel in the tourism industry. The company offers vacation packages, hotel stays, and air travel under the Transat and Air Transat brands. The company's core business consists of tour operators based in Canada that are vertically integrated with its other services of air transportation, distribution through a dynamic travel agency network, value-added services at travel destinations, and accommodations. Its geographical segments include the Transatlantic, Americas, and others.ZoomAway Technologies CVE:ZMAC$0.07 +0.02 (+27.27%) As of 09/2/2025ZoomAway Technologies Inc., an online travel company, provides tools and information to research, plan, book, and experience travel and destination services for business and leisure travelers. Its flagship project is ZoomedOUT, a travel, social, and gaming platform. The company was formerly known as ZoomAway Travel Inc. and changed its name to ZoomAway Technologies Inc. in April 2021. ZoomAway Technologies Inc. was incorporated in 1987 and is headquartered in Reno, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
